15,410% rally in 5 years! Multibagger Cupid shares jump 3% to hit fresh 52-week high
Cupid shares jumped hit a fresh 52-week high of Rs 368 on Friday, extending their rally for a fourth straight session. Earlier this month, Cupid raised its FY27 revenue and profit guidance for the second time in less than two weeks, targeting revenue of Rs 800 crore and net profit of Rs 250 crore for the financial year.
Cupid shares jumped more than 3% to hit a fresh 52-week high on Friday, extending gains in the multibagger stock, which has delivered nearly 8,700% returns over three years and more than 15,410% over five years.
The stock rose to Rs 368 apiece on the NSE, extending its rally for the fourth consecutive session. Cupid shares have gained more than 16% in a week, 30% in a month and 246% so far in 2026. The stock has surged 657% over the past year despite broader market weakness.
Earlier this month, the condom-maker announced the second increase in profit and revenue guidance in less than two weeks, with the company now expecting to post a revenue of Rs 800 crore and net profit of Rs 250 crore in the ongoing financial year 2027.
Cupid continues to witness strong business momentum in FY27, with Q2 FY27 total revenue expected to cross Rs 200 crore. It added that the FY27 guidance was raised due to sustained momentum across its key business verticals and improved visibility across domestic and international markets.
The FY27 outlook has been revised upward, supported by strong Q2 FY27 business momentum expected to continue and grow through Q3 and Q4 FY27, improved visibility across institutional and private markets, continued expansion of the domestic FMCG business, progress towards imminent operationalisation of the Palava facility, and sustained growth across the Company's healthcare, and personal care portfolio, Cupid said.
Looking ahead, Cupid expects to scale domestic FMCG distribution to deepen Cupid's presence across modern trade, general trade and pharmacy channels. It also plans to operationalise its Palava manufacturing facility to enhance production capacity, flexibility and supply capabilities across domestic and international markets. Expansion of healthcare and personal care portfolio through new products, regulatory approvals and wider commercialisation opportunities are also on the cards.
Cupid also aims to strengthen its international healthcare business by expanding institutional, government and private-market opportunities across geographies, as well as build regional manufacturing platforms through the proposed South African venture, creating a potential base for wider international market expansion. It also plans to explore strategic healthcare opportunities through partnerships and investments that complement Cupid's healthcare and personal care ecosystem.
The company manufactures and supplies male and female condoms, water-based lubricant jelly and IVD kits.
Related Stories
Gold prices near Rs 1.47 lakh/10 grams, silver falls by Rs 1,144/kg as traders await Fed rate signals. What lies ahead?
Gold prices edged lower while silver fell on MCX as investors awaited the US Federal Reserves upcoming policy decision for clues on interest rates. Traders expect rates to remain unchanged in October, with a possible hike in December. Analysts say dollar strength may cap golds upside, while central bank buying supports longer-term prices.
Infosys, TCS, Coforge, HCL Tech, TechM, Sagility: Selective rerating ahead, Jefferes shares target prices -
Infosys and TCS are seen as large IT companies offering 20 per cent-plus rerating potential in the best case. Sagility stands out among mid-sized companies, Jefferies said.
YES Bank share price targets: Goldman Sachs, Citi among 10 brokers with 'Sell' calls; what Nomura, others say -
Goldman Sachs has a target price of Rs 17 for YES Bank, while Citi sees the stock falling to Rs 16.50. Kotak Institutional Equities and Nuvama Institutional Equities have even lower targets of Rs 16.